Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s
The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY)...
NYSE: LLY
Eli Lilly China’s President Benjamin L. Basil to Depart for Personal Reasons
It has been reported that Benjamin L. Basil, the current president and general manager of...
Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults
Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...
Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US
Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I...
Eli Lilly’s Omvoh Receives FDA Approval for Ulcerative Colitis Treatment
The US Food and Drug Administration (FDA) has granted regulatory approval to Eli Lilly (NYSE:...
Biogen’s BIIB080 Shows Promise in Phase Ib Trial for Mild Alzheimer’s Disease
Biogen (NASDAQ: BIIB) has released preliminary findings from a Phase Ib trial for BIIB080, a...
Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio
US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink...
Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study
Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating...
FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment
The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for...
Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China
US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...
United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment
United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...
Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US...
Eli Lilly Sues US Sellers of Counterfeit Mounjaro Products
Pharmaceutical giant Eli Lilly (NYSE: LLY) has filed a lawsuit in the United States against...
Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors
Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to...
Eli Lilly’s Verzenios Receives NMPA Approval for Extended Indication in Early-Stage Breast Cancer
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has announced that the National Medical...
Eli Lilly’s Retevmo Meets Primary Endpoint in Phase III Trial for RET-mutant Medullary Thyroid Cancer
Eli Lilly (NYSE: LLY) has announced that its Phase III trial for the RET kinase...
Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio
Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ:...
Eli Lilly Completes Acquisition of Dice Therapeutics for $2.0 Billion
Pharmaceutical giant Eli Lilly (NYSE: LLY) has successfully concluded the purchase of US-based Dice Therapeutics...
Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials
US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for...